Dexmedetomidine Pharmacokinetics in Neonates with Hypoxic-Ischemic Encephalopathy Receiving Hypothermia
Dexmedetomidine is a promising sedative and analgesic for newborns with hypoxic-ischemic encephalopathy (HIE) undergoing therapeutic hypothermia (TH). Pharmacokinetics and safety of dexmedetomidine were evaluated in a phase I, single-center, open-label study to inform future trial strategies. We rec...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-01-01
|
| Series: | Anesthesiology Research and Practice |
| Online Access: | http://dx.doi.org/10.1155/2020/2582965 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850210208654032896 |
|---|---|
| author | Ryan M. McAdams Daniel Pak Bojan Lalovic Brian Phillips Danny D. Shen |
| author_facet | Ryan M. McAdams Daniel Pak Bojan Lalovic Brian Phillips Danny D. Shen |
| author_sort | Ryan M. McAdams |
| collection | DOAJ |
| description | Dexmedetomidine is a promising sedative and analgesic for newborns with hypoxic-ischemic encephalopathy (HIE) undergoing therapeutic hypothermia (TH). Pharmacokinetics and safety of dexmedetomidine were evaluated in a phase I, single-center, open-label study to inform future trial strategies. We recruited 7 neonates ≥36 weeks’ gestational age diagnosed with moderate-to-severe HIE, who received a continuous dexmedetomidine infusion during TH and the 6 h rewarming period. Time course of plasma dexmedetomidine concentration was characterized by serial blood sampling during and after the 64.8 ± 6.9 hours of infusion. Noncompartmental analysis yielded descriptive pharmacokinetic estimates: plasma clearance of 0.760 ± 0.155 L/h/kg, steady-state distribution volume of 5.22 ± 2.62 L/kg, and mean residence time of 6.84 ± 3.20 h. Naive pooled and population analyses according to a one-compartment model provided similar estimates of clearance and distribution volume. Overall, clearance was either comparable or lower, distribution volume was larger, and mean residence time or elimination half-life was longer in cooled newborns with HIE compared to corresponding estimates previously reported for uncooled (normothermic) newborns without HIE at comparable gestational and postmenstrual ages. As a result, plasma concentrations in cooled newborns with HIE rose more slowly in the initial hours of infusion compared to predicted concentration-time profiles based on reported pharmacokinetic parameters in normothermic newborns without HIE, while similar steady-state levels were achieved. No acute adverse events were associated with dexmedetomidine treatment. While dexmedetomidine appeared safe for neonates with HIE during TH at infusion doses up to 0.4 μg/kg/h, a loading dose strategy may be needed to overcome the initial lag in rise of plasma dexmedetomidine concentration. |
| format | Article |
| id | doaj-art-96d70fa6ad5e41efbd26b3378926076b |
| institution | OA Journals |
| issn | 1687-6962 1687-6970 |
| language | English |
| publishDate | 2020-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Anesthesiology Research and Practice |
| spelling | doaj-art-96d70fa6ad5e41efbd26b3378926076b2025-08-20T02:09:49ZengWileyAnesthesiology Research and Practice1687-69621687-69702020-01-01202010.1155/2020/25829652582965Dexmedetomidine Pharmacokinetics in Neonates with Hypoxic-Ischemic Encephalopathy Receiving HypothermiaRyan M. McAdams0Daniel Pak1Bojan Lalovic2Brian Phillips3Danny D. Shen4Department of Pediatrics, University of Wisconsin School of Medicine and Public Health, Madison, WI, USADepartment of Pharmacy, Seattle Children’s Hospital, Seattle, WA, USAClinical Pharmacology Sciences, Eisai Inc., Woodcliff Lake, NJ, USAPharmacokinetics Laboratory, Department of Pharmaceutics, School of Pharmacy, University of Washington, Seattle, WA, USAPharmacokinetics Laboratory, Department of Pharmaceutics, School of Pharmacy, University of Washington, Seattle, WA, USADexmedetomidine is a promising sedative and analgesic for newborns with hypoxic-ischemic encephalopathy (HIE) undergoing therapeutic hypothermia (TH). Pharmacokinetics and safety of dexmedetomidine were evaluated in a phase I, single-center, open-label study to inform future trial strategies. We recruited 7 neonates ≥36 weeks’ gestational age diagnosed with moderate-to-severe HIE, who received a continuous dexmedetomidine infusion during TH and the 6 h rewarming period. Time course of plasma dexmedetomidine concentration was characterized by serial blood sampling during and after the 64.8 ± 6.9 hours of infusion. Noncompartmental analysis yielded descriptive pharmacokinetic estimates: plasma clearance of 0.760 ± 0.155 L/h/kg, steady-state distribution volume of 5.22 ± 2.62 L/kg, and mean residence time of 6.84 ± 3.20 h. Naive pooled and population analyses according to a one-compartment model provided similar estimates of clearance and distribution volume. Overall, clearance was either comparable or lower, distribution volume was larger, and mean residence time or elimination half-life was longer in cooled newborns with HIE compared to corresponding estimates previously reported for uncooled (normothermic) newborns without HIE at comparable gestational and postmenstrual ages. As a result, plasma concentrations in cooled newborns with HIE rose more slowly in the initial hours of infusion compared to predicted concentration-time profiles based on reported pharmacokinetic parameters in normothermic newborns without HIE, while similar steady-state levels were achieved. No acute adverse events were associated with dexmedetomidine treatment. While dexmedetomidine appeared safe for neonates with HIE during TH at infusion doses up to 0.4 μg/kg/h, a loading dose strategy may be needed to overcome the initial lag in rise of plasma dexmedetomidine concentration.http://dx.doi.org/10.1155/2020/2582965 |
| spellingShingle | Ryan M. McAdams Daniel Pak Bojan Lalovic Brian Phillips Danny D. Shen Dexmedetomidine Pharmacokinetics in Neonates with Hypoxic-Ischemic Encephalopathy Receiving Hypothermia Anesthesiology Research and Practice |
| title | Dexmedetomidine Pharmacokinetics in Neonates with Hypoxic-Ischemic Encephalopathy Receiving Hypothermia |
| title_full | Dexmedetomidine Pharmacokinetics in Neonates with Hypoxic-Ischemic Encephalopathy Receiving Hypothermia |
| title_fullStr | Dexmedetomidine Pharmacokinetics in Neonates with Hypoxic-Ischemic Encephalopathy Receiving Hypothermia |
| title_full_unstemmed | Dexmedetomidine Pharmacokinetics in Neonates with Hypoxic-Ischemic Encephalopathy Receiving Hypothermia |
| title_short | Dexmedetomidine Pharmacokinetics in Neonates with Hypoxic-Ischemic Encephalopathy Receiving Hypothermia |
| title_sort | dexmedetomidine pharmacokinetics in neonates with hypoxic ischemic encephalopathy receiving hypothermia |
| url | http://dx.doi.org/10.1155/2020/2582965 |
| work_keys_str_mv | AT ryanmmcadams dexmedetomidinepharmacokineticsinneonateswithhypoxicischemicencephalopathyreceivinghypothermia AT danielpak dexmedetomidinepharmacokineticsinneonateswithhypoxicischemicencephalopathyreceivinghypothermia AT bojanlalovic dexmedetomidinepharmacokineticsinneonateswithhypoxicischemicencephalopathyreceivinghypothermia AT brianphillips dexmedetomidinepharmacokineticsinneonateswithhypoxicischemicencephalopathyreceivinghypothermia AT dannydshen dexmedetomidinepharmacokineticsinneonateswithhypoxicischemicencephalopathyreceivinghypothermia |